Recent News

• 04.02.2025 - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
• 04.02.2025 - Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
• 03.19.2025 - Stifel 2025 Virtual CNS Forum
• 03.19.2025 - Stifel 2025 Virtual CNS Forum
• 03.13.2025 - Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
• 03.13.2025 - Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
• 03.11.2025 - Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum
• 03.11.2025 - Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Recent Filings

• 03.31.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.31.2025 - S-3 Registration statement under Securities Act of 1933
• 03.31.2025 - ARS Annual Report to Security Holders
• 03.31.2025 - DEF 14A Other definitive proxy statements
• 03.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.13.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.13.2025 - 8-K Current report
• 03.13.2025 - EX-99.1 EX-99.1
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities